Post-clipping alopecia often has a poor clinical response to therapy and prolonged alopecia is a source of anxiety for some owners. In humans and dogs, superficial microtrauma using a microneedling device appears to induce mechanical stimulation of the hair follicle with resultant hair regrowth. Human studies suggest that application of platelet-rich plasma (PRP) in conjunction with microneedling induces more rapid regrowth of better quality hair than microneedling alone. Four unrelated dogs diagnosed clinically and histologically with post-clipping alopecia for greater than one year were studied. The affected site was divided in half, with the first half treated with microneedling alone (MN) then the other half treated with PRP followed by microneedling (PRP + MN). Microneedling was accomplished under heavy sedation by rolling a new sterile microneedling device with moderate pressure in all directions until capillary bleeding was achieved. Hair regrowth was assessed by clinician and owner on a hair growth assessment scale (HGAS) (0, no improvement; 1, 1-25% improvement; 2, 26-50% improvement; 3, 51-75% improvement; and 4, 76-100% improvement) at one, three and six months. At three months, no dogs were scored 0 and three of four dogs had greater hair regrowth on the PRP + MN half. At six months, both PRP + MN and MN sites had a similar response, where three of four dogs scored 4 and one dog scored 2 on HGAS. Statistics were not performed due to the small sample size. In dogs with post-clipping alopecia, PRP + MN appears to induce more rapid hair regrowth than MN.
A survey of antimicrobial use among dog breeders and prevalence of meticillin-resistant Staphylococcus spp. from the oral cavity and nares in individually owned breeding dogs
B. SIMON, A. SCHICK and T. LEWIS
Dermatology for Animals, Gilbert, AZ, USA Meticillin-resistant Staphylococcus pseudintermedius (MRSP) skin infections are an increasing concern in veterinary medicine. Previous reports have linked antimicrobial misuse in breeding kennels with increased risk of resistant staphylococcal strains. Additionally, there has been increased recognition of MRSP infections in juvenile dogs with no prior antibiotic exposure. The objectives of this study were to assess the prevalence of meticillinresistant coagulase-positive staphylococci in breeding bitches and to survey antibiotic administration by their owners. A total of 17 breeders participated, and 54 bitches of various ages and breeds were included. The bitches were kept in diverse housing environments throughout the Phoenix, AZ, metropolitan region. Nasal and oral swabs were taken and submitted for aerobic bacterial culture. Susceptibility to oxacillin and the presence of the mecA gene were determined for each isolate. PBP2a latex agglutination testing revealed that 0 of 54 samples were positive for meticillin-resistant Staphylococcus aureus and one of 54 samples was positive for MRSP. These findings were interesting to note, as previous publications revealed that all isolated strains of S. pseudintermedius obtained from breeding bitches showed high percentages of resistance to various antimicrobials, yet were meticillin-sensitive. Survey results revealed that 16 of 54 bitches received antibiotics within the year prior to sampling, including the bitch in which the MRSP positive sample was obtained. However, due to the paucity of positive cultures, no statistically significant correlations could be made. Despite our findings, veterinarians and dog breeders should be cognizant of the risk for antimicrobial resistance with the overuse of antimicrobials.
gastrointestinal signs, and pedal cytological findings between healthy and nonhealthy EBDs; and to assess the frequency of dermatological abnormalities and cytological findings of lesional and nonlesional paw sites in nonhealthy EBDs. Show bulldogs (n = 34) received dermatological examinations. Impression smear cytological samples were taken from the dorsal and palmar/plantar paw. Pruritic behaviours, gastrointestinal signs and antimicrobial and/or immunomodulatory drugs received within 12 months of show also were assessed. The dog owners completed questionnaires regarding history and assessed pruritus. No dogs met the standard criteria for healthy, and thus comparison between healthy and nonhealthy EBDs was not possible: 100% had an abnormal dermatological examination with at least one site of erythema; 65% had recent drug history; 47% had history of dermatological disease; 41% had history of other disease; 32% had history of pruritus; and 26% had history of gastrointestinal disease. Compared to published normal values, EBD gastrointestinal signs differed in eructation, flatulence and regurgitation. Pedal erythema affected 94% of paws but did not correlate with pruritus or cytological findings. Sixty one percent of paws had nuclear streaming or polymorphonuclear cells on cytological evaluation. White coloured pedal exudation correlated with inflammation and cocci, otherwise lesions did not correlate with cytological findings. No show EBDs met the criteria for healthy and cytological evalution was overall poor in distinguishing lesional from nonlesional skin.
Source of funding: Self-funded.
Conflict of interest: None declared.
Bromelain-based enzymatic debridement of deep burns on the paws of a cat
L. WALDMAN

Veterinary Dermatology and Allergy Clinic, Haifa, Israel
A bromelain-based proteolytic enzyme preparation (NexoBrid TM ) is used for the treatment of moderate and deep burns in humans. It removes eschar while preserving healthy dermis, which improves healing and reduces the need for repeated general anaesthesia, surgery and autografting. A 13-year-old male, neutered, domestic medium hair cat suffered smoke inhalation, feline lower urinary tract disease and severe burns to all paws in a forest fire. After cleaning the paws, the bromelain-based proteolytic enzyme preparation was applied under occlusive dressing for 4 h resulting in complete debridement down to healthy dermis. To prevent drying, the wounds were treated, without dressings, with sea buckthorn oil thrice daily for six weeks. The day after the bromelain-based proteolytic enzyme preparation treatment, the cat began to walk cautiously to the litter tray. Pseudoeschar formed within 2 days. Granulation tissue appeared after 6 days and clobetasol propionate 0.05% cream (Dermovate â ) was then applied thrice daily for six weeks to inhibit further granulation tissue formation. Pain was controlled with oral buprenorphine 0.025 mg/kg four times daily for the first two weeks, then oral meloxicam 0.2 mg/kg for 1 day followed by 0.05 mg/kg once daily for 6 days. A week after debridement, the cat was alert, walking in the house and eating well, despite signs of painful paws. Five weeks later, adhesions in the left hind paw were surgically released. In conclusion, a bromelain-based proteolytic enzyme preparation developed for the treatment of human burns successfully treated deep paw burns in a cat without the need for intensive wound care.
Source of funding: NexoBrid TM donated by MediWound Ltd; otherwise self-funded.
Conflict of interest: None declared.
Use of the Health Belief Model to assess adherence to elimination diet trials in veterinary medicine M. R. PAINTER*, T. TAPP † and J. PAINTER ‡ *Animal Dermatology Clinic, Tustin, CA, USA †Veterinary Healing Arts, East Greenwich, RI, USA ‡George Mason University, Fairfax, VA, USA
The current gold standard diagnostic test for cutaneous adverse food reaction (CAFR) in dogs is an elimination diet trial (EDT). The diagnostic value of this test relies on sustained adherence to strict feeding guidelines. The purpose of this study was to assess demographic, knowledge and psychosocial factors associated with selfreported adherence to EDT recommendations. Owners of canine patients who were prescribed an EDT to diagnose CAFR in the past 5 years (2012) (2013) (2014) (2015) (2016) (2017) were identified through a medical records review from a single veterinary dermatology specialty practice in East Greenwich, RI, USA. Potential participants (n = 665) were contacted by e-mail and invited to participate in an online survey. Survey items were guided by the Health Belief Model, a widely used public health framework to assess how psychosocial attitudes impact health behaviours. Multivariable logistic regression was conducted to assess factors associated with self-reported adherence to EDT recommendations. Of 192 survey participants, 77 (40.1%) reported perfectly strict EDT adherence. In multivariable analyses, participants with increased barriers (aOR = 0.88, P = 0.013) were significantly less likely to report strict EDT adherence. Participants with increased knowledge (aOR = 1.30, P = 0.049) or self-efficacy (confidence in their ability to follow strict adherence guidelines) (aOR = 1.18, P = 0.014) were significantly more likely to report strict EDT adherence. These findings indicate that the majority of EDTs prescribed are not followed strictly. Interventions which help clients reduce perceived barriers, increase self-efficacy and improve knowledge could improve adherence to EDT instructions and increase the utility of this diagnostic test. Meticillin-resistant (MR) staphylococcal pyoderma in dogs has led to increased use of rifampicin (RFP). Although RFP exhibits bactericidal activity against Staphylococcus spp. in humans, this has not been studied in dogs. The study objectives were to determine the minimum inhibitory concentration (MIC) of canine Staphylococcus intermedius group (SIG) organisms and to determine the killing properties of rifampicin. One hundred canine SIG isolates -50 meticillin-susceptible (MS) and 50 MRwere used to determine the MIC of RFP using the E-test. Two MS-SIG isolates with an MIC of 0.003 and 0.008 lg/ mL and two MR-SIG isolates with an MIC of 0.003 and 0.012 lg/mL were used for time-kill studies. Mueller Hinton Broth was supplemented with RFP at 0, 0.5, 1, 2, 4, 8, 16 and 32 times the MIC of the respective isolate for 0, 2, 4, 10, 16 and 24 h. The number of viable colony forming units (cfu) was determined using the BacTiter-Glo TM Microbial Cell Viability Luciferase kit. The MIC50 was 0.004 lg/mL and the MIC90 was 0.008 lg/mL. Based on these methods RFP activity against all four isolates was consistent with time-dependent response because the magnitude of decrease in cfu was unchanged regardless of antimicrobial concentration. Two isolates (MS-SIG 0.003 and 0.008 lg/mL) exhibited bacteriostatic activity, whereas the other isolates (MR-SIG 0.003 and 0.012 lg/ mL) exhibited bactericidal activity. This study determined the MIC of RFP in canine SIG isolates, demonstrated that MS-and MR-SIG isolates are equally susceptible to RFP, and recommends dosing intervals designed for timedependent efficacy.
Zinc-responsive dermatosis in a French bulldog P. BLOOM Allergy, Skin and Ear Clinic for Pets, Livonia, MI, USA Zinc-responsive dermatosis (ZRD) has been associated with two different aetiologies. Type I ZRD is seen almost exclusively in Nordic breeds and thought to occur due to a decrease in zinc absorption. Type II ZRD is seen in rapidly growing large-breed puppies or young adults and is due to inadequate zinc in the diet or due to dietary components inhibiting or reducing zinc absorption. Clinically ZRD is characterized by erythema, thick adherent scaling, crusting, alopecia and lichenification. Distribution of the lesions most commonly involves the pinnae, periorbital, areas, mucocutaneous junctions and pressure points. ZRD has been reported in Boston terrier dogs. This is a case report of ZRD in a French bulldog (FBD). A 5-month-old intact male FBD presented with a 2.5 month history of a nonpruritic crusting pinnal dermatitis. The puppy was eating a national brand puppy food. On examination there was severe, thick adherent scale/ crust along the margins of both pinnae creating a scalloped appearance. Histopathological examination of the left pinna revealed marked laminar orthokeratotic to parakeratotic hyperkeratosis that distended follicular ostia with large accumulations of serum. There was mild perivascular lymphoplasmacytic dermatitis. Treatment with 2 mg/kg zinc methionine (NutriVed Chewable Zinpro â ) once daily per os was begun. There was dramatic improvement by Day 60 post treatment and complete resolution of the lesions by Day 90. To the author's knowledge, this is the first report of Type I ZRD in a FBD.
Efficacy of oral afoxolaner for the treatment of canine generalized demodicosis in Japan N. MURAYAMA and Y. OSHIMA Dermatology Services for Dogs and Cats, Koto-ku, Tokyo, Japan Canine demodicosis presents with various skin lesions and severe cases can be difficult to control. This study assessed the efficacy of afoxolaner (Nexgard Spectra â ) at the dosage of 2.5-6.3 mg/kg per os every four weeks in dogs with juvenile-onset (n = 4) and adult-onset (n = 11) generalized demodicosis. Fifteen client-owned dogs diagnosed with generalized demodicosis were included in this study. Deep skin scrapings at five affected areas and clinical evaluations including alopecia, erythema, papules, pustules and crusts/scales were performed every four weeks for three months. Skin biopsies were performed from representative skin lesions on Day 0 in all dogs. Histopathological findings showed lymphocytic mural folliculitis (13 of 15), follicular hyperkeratosis (nine of 15), pyogranulomatous dermatitis (five of 15) and subcorneal pustules (two of 15). The rate of decrease in mite counts was 91.2, 99.8 and 99.9% on days 28, 56 and 84, respectively. In five dogs with pyogranulomatous dermatitis, the rate of decrease was 76.4, 99.58 and 100% on days 28, 56 and 84, respectively, whereas the rate of decrease was 98.7, 99.9 and 99.9% on days 28, 56 and 84, respectively, in the other 10 dogs. Skin lesions showed significant improvement on days 56 and 84. No statistically significant difference was noted in the reduction of mite counts and improvement of skin lesions except papules on Day 56 (P = 0.008) between dogs with pyogranulomatous dermatitis and those without pyogranulomatous dermatitis. No adverse effects were observed in any dogs. In conclusion, afoxolaner administered every four weeks could be a treatment for dogs with generalized demodicosis presenting with various skin lesions. Staphylococcus pseudintermedius is the most frequent pathogen isolated from skin and ear infections in dogs and cats. Extensive and repeated treatments with systemic antimicrobials contribute to the development of resistance. Topical therapy, including the use of antiseptics (e.g. chlorhexidine), is very important in antimicrobial stewardship. Investigations are necessary to better understand the effect of other topically applied ingredients. This study was performed to demonstrate the effectiveness of phytosphingosine against S. pseudintermedius. First, the minimum inhibitory concentration (MIC) of phytosphingosine hydrochloride (HCl-PS) was determined for 10 strains of S. pseudintermedius. Second, 7-h-old biofilms containing approximately 6 log 10 S. pseudintermedius in a 24-well plate were exposed to 0.1% (m/v) of HCl-PS, 0.3% (m/v) chlorhexidine digluconate or vehicle negative control. After 10 min at room temperature, the biofilms were rinsed twice and the bacteria in each well were counted before and after 15 min ultrasounds. For the 10 tested strains, the MIC of HCl-PS was below 0.003% (m/v), which is below its concentration in commercial products. After 10 min exposure to 0.1% (m/v) HCl-PS, biofilm-embedded bacteria were not detected in six of six wells. Biofilm bacteria also were reduced by 0.3% chlorhexidine digluconate but completely undetected in only two of six wells. The vehicle had no effect on the bacteria. Under our in vitro conditions, HCl-PS was successful in reducing S. pseudintermedius biofilm. These results suggest that topical products containing phytosphingosine could be effective in reducing S. pseudintermedius biofilm on skin and ears in dogs and cats. Health education is important for changing behaviours and increasing adherence. Pet owners frequently consult online sources of veterinary health information, yet there are limited data on its readability and also whether it is consistent with pet owner education levels. To evaluate the education level of the US pet-owning population, an analysis was performed on the questionnaire responses of 10,294 individuals in the National Health and Nutrition Examination Survey (NHANES), a nationally representative cross-sectional sampling. A subpopulation of 4,933 adults, representative of a population of 208,525,282, answered NHANES demographic and pet questions. The age adjusted prevalence of high school graduation for adult pet owners was 85.8% AE 1.33 and higher than that for adults without pets (78.5% AE 1.5, P < 0.0001). To evaluate the readability of veterinary health information, Flesch Reading Ease Scores and Flesch-Kincaid Grade Level Scores were calculated for allergy information at three veterinary health websites (28 articles) and compared to that at three human health websites (26 articles). Veterinary websites offered health information that was more difficult to read (P = 0.0052) and written at a higher grade level (P = 0.0047) than that at human health websites. The average veterinary health information readability score was 45.9 AE 8.7 ('difficult to read') and written at an 11th grade level or above (range: 8th grade -college level). Because literacy skills can lag behind education level, further studies are needed to evaluate reading comprehension of health information by veterinary consumers.
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Preliminary results from a mobile app monitoring canine pruritus and quality of life in dogs prescribed oclacitinib A. WRIGHT, C. ALAMAN and R. HOLLAND Zoetis, Parsippany, NJ, USA Oclacitinib (Apoquel â ) is for treatment of allergic pruritus in dogs. A mobile app (PicorCan) activation code was given by veterinarians to 30 dog owners at the time that oclacitinib was dispensed. Owners entered contact details and treatment start date and days of therapy (mean = 11.8 days, R = 2-30). Owners were prompted to choose emoticons (a representation of a facial expression from frowning to smiling on a scale of 1-5) for their dog and themselves, pruritus scores and Canine Dermatitis Quality of Life (QoL) and Treatment Satisfaction Questionnaire (CDQoL-TSQ), measuring QoL for themselves and their dog before and 24 h after treatment completion. Veterinarians accessed a portal (VetSupport+) to monitor the response to oclacitinib. Ninety percent (27 of 30) of owners started their surveys within 1 day. Twenty percent (six of 30) of owners selected the human emoticon for themselves on Day 0 increasing to 100% post-treatment, with an average score 4. One hundred percent (30 of 30) of dog owners selected the dog emoticon with an average initial score of 2, rising to 4 post-treatment. The average pruritus score on a scale of 1-10 was 6.73 on Day 0 decreasing to 3.13 post-treatment. The dogs' average calculated CDQoL-TSQ score before treatment was 54 of 100 and improved to 78 of 100 post-treatment. The owners' CDQoL-TSQ score pre-treatment was 40 of 100 and improved to 54 of 100 post-treatment. Preliminary results show that a mobile application is accepted by owners for monitoring pruritus and response to oclacitinib and has the potential to enhance communication between veterinarians and dog owners. 0.41-0.60) . A previously undescribed observation of the 'round hair tip' was made and it was more commonly found on the dorsal head. Colour change to the proximal hair shaft was more common on the thighs and flanks. This study establishes normal trichographic findings in 500 hairs from 20 healthy black DP. It describes a systematic approach for evaluating hair shafts that can be applied in future studies for both normal and abnormal DP.
Conflict of interest: None declared. Source of funding: Self-funded.
KT is an employee of the Veterinary Information Network.
Ex-vivo boosted immune cell therapy for canine chronic ulcerative dermatitis in a dog
S. G. BAE, J. T. KIM and T. H. OH
Laboratory of Veterinary Dermatology, Kyungpook National University, Daegu, Korea
A 13-year-old, neutered male shih tzu presented after nine weeks of ineffective treatment with topical and systemic antibiotics, and anti-inflammatory and immunosuppressive doses of prednisolone for an exudative, ulcerative dermatitis. Physical examination revealed a pruritic, bilaterally symmetrical severely erythematous, exudative and ulcerative dermatitis with superficial crusts affecting the periocular, pinnal, axillary, inguinal, hind limb and perianal regions. Complete blood count revealed leucopenia. Skin cytological evaluation revealed numerous neutrophils and intracellular and extracellular cocci. A diagnosis of canine chronic ulcerative dermatitis with bacterial dermatitis was made histopathologically. Based on the antibiotic susceptibility results, the dog was treated with oral chloramphenicol (40 mg/kg) and amoxicillin/ clavulanate (20 mg/kg) both twice daily for two weeks. However, the skin lesions progressed, most notably with worsening of the exudate and pruritus, despite antibiotic therapy. Following consultation with the dog's owner, the decision was made to treat with ex-vivo boosted immune cell (EBIC) therapy and the same previous antibiotics.
For EBIC therapy, the dog's peripheral blood mononuclear cells were isolated, cultured and expanded for two weeks. The expanded immune cells were infused intravenously every two weeks, for a total of six infusions. No adverse events were observed during therapy. After six EBIC therapy infusions, all skin lesions had resolved completely and no recurrence was noted for two years. This is the first report to describe a case of canine chronic ulcerative dermatitis with bacterial dermatitis refractory to several topical and systemic antibiotics and prednisolone that responded to boosted immune cell therapy combined with systemic antibiotics.
Source of funding: Self-funded. Oclacitinib (Apoquel â ) is prescribed for the treatment of pruritus associated with allergic dermatitis and atopic dermatitis in dogs. This study gathered signalment, diagnosis and days 0 (pre-) and 7 (post-treatment) pruritus Visual Analog Scale (VAS) scores from 64 dogs in general practice treated with oclacitinib for acute pruritus. An ownercompleted Canine Dermatitis Quality of Life (CDQoL-TSQ) questionnaire (including separate scales for dog and owner QoL) was completed and scored on days 0 (pre-) and 7 (post-treatment). Associations between dose, study day and other predictors with QoL scores in dogs and owners were tested using generalized linear mixed models and fitted with a beta distribution, logit link and residual pseudo-likelihood in SAS (SAS 9.4, SAS Institute Inc.). Independent variables tested included: dose, study day, pruritus score, dog's age, weight, sex and diagnosis [categorical: 1, allergic dermatitis; 2, acute flare of atopic dermatitis; 3, other (flea allergy undergoing flea control trial, food allergy undergoing diet trial, allergen testing, ongoing allergen-specific immunotherapy and other)]. Based on unconditional analysis, only study day and pruritus score were significantly associated (P < 0.001) with QoL of dogs. Results from uni-variable models indicate that, as for QoL of dogs, only study day (P < 0.001) and pruritus score were significantly associated (P < 0.001) with owner QoL. Owner QoL increased significantly from Day 0 to Day 7; QoL decreased significantly as the pruritus score increased. QoL of acutely pruritic dogs and their owners improved in 7 days with oclacitinib. There has been an increase in meticillin-resistant Staphylococcus pseudintermedius infections in dogs, with most being multidrug-and extensively drug-resistant. Alternatives to antibiotics are needed to control staphylococcal infections. We found that the bacteria inhibit phagocytosis, neutralize complement, bind immunoglobulin, induce B-cell apoptosis and secrete leucotoxins. The purpose of this study was to identify antigens of S. pseudintermedius, modify them, and test their antigenicity in vivo and in vitro. We developed a vaccine composed of antigens from key S. pseudintermedius defensive and offensive proteins secreted and/or exposed on the bacterial surface. Recombinant proteins attenuated by amino acid substitutions and antigenically very similar to the corresponding native proteins but without toxic and immune suppressive properties were produced. The proteins included coagulase, leucotoxin ED, protein A, 5 0 -nucleotidase and exotoxin-15. Three injections were given subcutaneously to healthy dogs 1 week apart. Serum was collected before vaccination and weeks 1, 2, 3 and 5 post-vaccination. Complete blood count and chemistry panels were assessed at weeks 0 and 5 with no abnormalities noted. A good antibody response was obtained from individual proteins (100 lg/injection), a protein mixture (20 lg of each protein in one vaccine) and a single chimeric protein with no adverse reactions. The antibodies neutralized the superantigenic effect of protein A (85% reduction in activity), overcame canine neutrophil migration inhibition by exotoxin-15 (55.5% improvement in neutrophil migration) and prevented coagulation of plasma by coagulase. These results show the identified proteins to be antigenic and nontoxic. The vaccine will be tested in a clinical trial.
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technique that can be used to desensitize the ear canal. Eight canine cadavers (two fresh, six thawed), for a total of 16 ears, were used. An anatomical study of the nerves supplying the ear canal was performed in two ears. For the remaining 14 ears (seven left, seven right), the cadavers were placed in lateral recumbency and injections of dye were performed using methylene blue (1:1 ratio sterile saline) using a volume of 0.1 mL/kg (maximum 3 mL) for each injection site. For each ear, two dye injections were performed targeting the auriculotemporal nerve (AT), rostral to the ear canal and caudal to the zygomatic arch, and the greater auricular nerve (GA), ventral to the wing of the atlas and caudal to the tympanic bulla. Bilateral dissection was performed following the injections and the accuracy of dye deposition was determined. Successful nerve staining was defined as nerves stained for a length >6 mm. Occurrence of facial nerve (FN) staining also was recorded. Nerve staining was 93 and 100% successful for AT and GA, respectively. Staining of FN was 71%. Based on our nerve-staining criteria, the described approach should provide acceptable sensory blockade of the canine ear canal. Due to the high prevalence of FN staining, eye lubrication may be needed until the effect of blockade has resolved. Canine atopic-like dermatitis (ALD) has identical clinical manifestations to atopic dermatitis (AD); however, allergen-specific IgE cannot be detected in this disease subset. The primary study aim was to compare clinical and epidemiological features of dogs with ALD and AD. Atopic dogs with available intradermal and serum allergen test results were selected retrospectively. Inclusion criteria were met by 253 dogs. Dogs were enrolled in the ALD group if both allergen tests were negative and in the AD group if at least one test was positive. In addition, dogs in the ALD group that were positive on a food elimination trial were excluded from the study. Epidemiological data, disease severity measured by pruritus level, number of body sites affected and maintenance therapy in addition to response to therapy were compared between the groups. Two hundred and sixteen (85.38%) dogs were included in the AD group and 37 (14.62%) in the ALD group. No significant differences were noted between the groups regarding the epidemiological variables evaluated. There were no differences in the mean pruritus scores and number of affected body sites at the first visit (P = 0.433 and P = 0.474, respectively) or during treatment (P = 0.949 and P = 0.093, respectively) between groups. Moreover, no differences in the reduction of pruritus (P = 0.061) and number of body sites affected (P = 0.368) were observed during treatment between groups. In conclusion, no significant differences in the epidemiological data and clinical features evaluated were noted between dogs with ALD and AD.
Source of funding: Self-funded. Scratching behaviours associated with intradermal injection of pruritogens such as histamine and compound 48/80 into the skin of mice and humans is the commonly used model to advance itch research and drug development. However, the predictive validity of this model is poorly documented in dogs. In the present study, we evaluated the dose-dependent effects of established pruritogenic substances, each with a different mechanism of action, in 10 healthy beagle dogs. All dogs were videorecorded for 30 min after the intradermal injections of goat anti-canine IgE (4 and 25 lg/site), histamine and compound 48/80 (50, 100 and 200 lg/site); two buffered saline injections served as controls. All dogs showed wheal and erythema at the pruritogen injection site; global wheal scores at 30 min post-injection of each substance significantly increased at all concentrations compared to control (one-way ANOVA, P ≤ 0.05). A blinded evaluation revealed that all pruritogens induced acute pruritic behaviours at the site of injection in six of 10 dogs. There was no injection site pain seen in any dog. Compared to controls, injections of pruritogens did not significantly affect the pruritic seconds or occurrence of pruritic episodes for any of the substances. There was no dose-dependent increase in pruritic behaviour observed for any of the concentrations except for compound 48/80 (one-way ANOVA, P = 0.11). These preliminary results suggest that intradermal injections of studied pruritogens can induce itch and inflammation in healthy dogs; but inconsistencies occur in the induction of itch with different concentrations of pruritogen within the same dogs.
Source of funding: Self-funded. There is increased use of rifampicin (RFP) in dogs; however, neither pharmacodynamics (PD) nor pharmacokinetics (PK) are available. This study aimed to determine the PK and PD of RFP in dogs. Ten healthy dogs were dosed orally with RFP at 5.9 AE 1.1 mg/kg every 24 h for 13 days. On Day 14, a trough plasma sample was collected; dogs received a single equivalent intravenous RFP dose and plasma was sampled intermittently for 48 h. Dogs were monitored throughout the 14 day period for adverse events, including physical examination and blood work. Nares and mouth cultures were collected on days 0 and 14. After oral dosing on Day 7, C max was 8.3 AE 4.9 lg/mL. After intravenous dosing on Day 14, C max was 21.5 AE 3.9 lg/mL and 3.7 AE 0.7 lg/mL when adjusted for dose. AUC ∞ was 57 AE 12 h (lg/mL), CLss was 0.019 AE 0.004 L/kg/h, Vd was 0.28 AE 0.9 L/kg and t 1/2 was 10.7 AE 1.7 h. Based on a Staphylococcus intermedius group (SIG) minimum inhibitory concentration (MIC) 90 of 0.008 lg/mL for RFP, integration of PK and PD revealed a T>MIC of 48 h and an AUC:MIC 90 of 7087 AE 1.7. RFP C max and C min exceeded the MIC 90 by more than 2,500-and 125-fold, respectively. No significant adverse events occurred in any dog. RFP-resistant SIG was cultured from three dogs at study end but in no dogs at study start. This study provides supporting evidence for clinical trials evaluating oral RFP at 5 mg/kg every 24 h in the dog. Future studies are needed to support lowering the dose beyond what was tested herein.
Source of funding: Self-funded. Tick bites and acarine hypersensitivity reactions cause skin damage and irritation to hosts. The tick-host interface has not been described in domestic cats. The purpose of the present study was to characterize the histopathological changes induced by adult Amblyomma americanum bites on tick-na€ ıve domestic cats (Felis catus). Six purpose-bred domestic cats (three males, three females) were used. Skin biopsies were collected from normal skin prior to tick infestation. Each cat was infested with 50 laboratory-reared, pathogen-free A. americanum adults. Subsequent biopsies were collected at 24, 48 and 96 h post-infestation at tick-bite sites. By 24 h post-infestation, mild, focal epidermal necrosis was observed, with a minimal increase in dermal inflammatory infiltrates. The tick feeding cavity extended through the epidermis into the dermis within 24 h of infestation. By 48 h post-infestation, inflammation extended into the dermis and subcutis; the predominant patterns included a moderate perivascular neutrophilic dermatitis and a moderate diffuse neutrophilic panniculitis. Coagulated collagen degeneration was observed in the dermis by 48 h. By 96 h post-infestation, a focally severe neutrophilic dermatitis and panniculitis was observed, with focal areas of necrosis and fibrin deposition extending through the subcutis into the muscle band of the deep subcutis. The histopathological changes observed in this study incorporate specific responses previously described at the tick-host interface of dogs, cattle, rodents and lagomorphs. With the increased prevalence of meticillin-resistant Staphylococcus pseudintermedius and other multi-drug resistant bacterial pathogens, treatments options are becoming limited. Oxyclozanide is in the anthelmintic drug class called salicylanilide which has been used mainly as a flukicide in ruminant veterinary medicine. It concentrates in the intestinal tract but has poor systemic gastrointestinal absorption. There is one report of a salicylanilide known as closantel that was used as a parenteral treatment for canine demodicosis with some success. Oxyclozanide also has in vitro bactericidal activity against Staphylococcus aureus in humans but its activity against common small animal bacterial pathogens such as S. pseudintermedius has yet to be studied. The aim of this study was to measure and establish the minimum inhibitory concentration (MIC) and mutant prevention concentration (MPC) of oxyclozanide against S. pseudintermedius. The MIC and MPC were determined from 17 S. pseudintermedius isolates as well as one isolate strain each of S. aureus, Escherichia coli, Pseudomonas aeruginosa and Enterococcus faecalis with oxyclozanide using agar plate assays. The MIC of 16 of 17, and one of 17 isolate strains was 0.5 and 1 lg/mL, respectively. The MPC ranged between 16 and 32 lg/mL among all strains of S. pseudintermedius. No inhibition of growth was seen when testing bacterial isolate strains E. coli, P. aeruginosa and E. faecalis. These results show that oxyclozanide has in vitro antibacterial activity against S. pseudintermedius. Further studies are needed to evaluate the potential use of oxyclozanide as a topical or parenteral bactericidal agent.
Source of funding: Self-funded. Canine otitis externa is a common disease. Cytological evaluation of otic exudate is a useful diagnostic test to direct and monitor treatment for otitis externa. The conventional method of collecting ear cytological specimens utilizes a cotton tip swab inserted into the vertical ear canal. A proposed alternative method was to aspirate exudate from the deep horizontal canal using a rubber tube. The aim of this study was to compare cytological findings between these two collection techniques in 30 cases of canine otitis externa. This was a prospective, randomized, blinded comparison study. Ear canals from each dog were sampled using both methods. Ear cytological preparations were stained with Diff-Quik â and blindly evaluated by two investigators for polymorphonuclear leucocytes (PMN), monocytes/lymphocytes, macrophages, yeast, intracellular (IC) cocci, extracellular (EC) cocci, IC rods and EC rods. A paired t-test was used to compare the two techniques. The interinvestigator reliability for PMN, EC rods and yeast was good and for EC cocci was moderate. There were significantly higher numbers of PMNs obtained by the tube method (P = 0.0024) than the cotton swab method. There were no statistically significant differences between cotton swab and rubber tube methods for monocytes/lymphocytes (P = 0.7780), macrophages (P = 0.1751), EC cocci (P = 0.1262), EC rods (P = 0.1162), yeast (P = 0.5371), IC cocci (P = 0.6606) or IC rods (P = 0.6761). The technique was well tolerated. An alternative ear cytological collection technique was identified which enables sampling of the deep horizontal canal.
Source of funding: Self-funded. Erythema multiforme (EM) has been reported in humans, dogs and cats. In humans, a localized form of EM has been associated with lymphatic obstruction, Anthrax vaccination and radiation port site. An 8-year-old female spayed German shepherd mixed breed dog presented with skin lesions that developed 5 days after surgery for a ruptured right cruciate ligament. The lesions were multifocal raised annular and 'targetoid', some with a central erosion, others with a central crust, and a few with hair and underlying normal appearing skin. All lesions were localized to the right hip region that was subjected to a clipper burn incurred during a routine aseptic skin preparation that involved clipping with a size 40 blade, followed by alternating scrubs of povidone iodine (7.5% iodine) and isopropyl alcohol (91%) for a total of three times each, then a final iodine solution (10% iodine) was used. The adjacent region that was also clipped and aseptically prepared in a similar way but without thermal burn appeared clinically normal. Histopathological examination of the lesions showed lymphohistiocytic interface dermatitis with diffuse, moderate individual cell necrosis at multiple epidermal levels consistent with EM disease complex. The skin lesions resolved spontaneously without treatment. Proposed pathogeneses of localized EM in this dog include direct viral infection of keratinocytes by clipper blade transfer through epidermal injury, leading to cytotoxic lymphocytic reaction or a dysimmune cutaneous reaction due to thermal burn-associated disruption of lymph circulation and peripheral nerve fibre damage (known as immunocompromised cutaneous district in humans).
Source of funding: Self-funded. The study objective was to describe the clinicopathological features and treatment outcomes in cases of feline pemphigus foliaceus. Forty nine cats met inclusion criteria requiring a histopathological diagnosis and medical records available for review: 28 spayed (57%) and two intact (4%) females, and 19 castrated males (39%). The majority of cats [32 of 49 (65%)] were domestic short, medium or long hair. Median age at presentation was 6 years (range: five months-15 years). Skin lesions included crusts (100%), alopecia (76%), erythema (73%), erosion/ulceration/excoriation (61%) and pustules (22%). Pruritus and pain were noted in 63% and 22% of cats, respectively. Affected sites included pinnae (92%), head/ haired face (88%), nasal planum, philtrum and alar folds (57%), ungual folds (47%), perineum (33%) and peri-areolar region (27%). Disease onset was temporally associated with recent vaccination in two cats and pregnancy/ parturition in two cats. When evaluated, anaemia, leucocytosis, neutrophilia and hyperglobulinemia were commonly noted. Histological slides were available for review in 46 cats and eight cats had suggestive vasculopathic changes. Complete remission was noted in 33 cats: 22 cats received corticosteroid monotherapy and 11 cats received corticosteroids with ciclosporin, chlorambucil or gold salts. Twenty six cats received oral antibiotics concurrently for superficial pyoderma. Relapse occurred in 19 cats and was commonly associated with tapering/discontinuation of immunosuppressive medications. Complete discontinuation of immunosuppressive medications was not recorded in any cat. Spontaneous remission without treatment was noted in one cat with suspected metastatic thyroid carcinoma. Results indicated that cats with pemphigus foliaceus generally responded favourably to treatment and required long-term therapy. Canine epidermal keratinocytes (CPEKs) are widely used as canine keratinocyte cell line. It is unknown if CPEKs are suitable for studies evaluating barrier function and tight junctions. A widely accepted method to evaluate skin barrier is the measurement of transepithelial electric resistance (TEER). Our study aimed to compare TEER and tight junction (TJ) protein expression in CPEKs and primary canine keratinocytes from normal dogs in culture until Day 6. Although TEER measurements in primary canine keratinocytes readings increased overtime to 2,000 ohms/cm by Day 6, CPEKs readings stayed around 100-150 ohms/cm. Student's t-test of the TEER values showed significant difference between CPEKs and normal primary canine keratinocytes (P = 0.0275). TJ proteins (ZO1, claudin-1) were visualized by immunofluorescence. Slides were fixed on Day 0 of confluence and stained with ZO1 and claudin-1 antibodies. Five images of each antibody were taken, randomized and evaluated blindly by three investigators for intensity, staining location, granularity, uniformity and continuity. Cell size and variability of size were evaluated. Because we only had one slide of CPEKs cells per antibody, we tested our scores with a single sample z-score test. The size of CPEKs cells was significantly (P < 0.0001) smaller than primary normal keratinocytes and less variability of size was detected. For claudin-1, intensity of staining was greater in CPEKs (P = 0.00362), whereas granularity was less in CPEKs (P < 0.0001). No significant differences were seen for ZO1. In conclusion, CPEKs may not be representative of normal primary keratinocytes in terms of creating an effective skin barrier. Immune-modulating drugs show limited therapeutic efficacy in canine exfoliative cutaneous lupus erythematosus (ECLE); over half of ECLE dogs are eventually euthanized for their lack of response to therapy. We report herein a case of generalized ECLE in a dog in which mycophenolate mofetil (MMF) treatment achieved complete remission. A 3-year-old, male castrated German shorthair pointer was presented with a three month history of generalized scaling, follicular casts and hypotrichosis affecting the head, trunk, ventrum and medial aspects of all limbs. Severe erythema and well-demarcated annular to polycyclic, hyperpigmented macules and plaques were present on the ventral abdomen, axillae, inguinal area and limbs. The patient exhibited lameness and stiff gait. Histologically, skin biopsy specimens revealed lymphocyterich interface dermatitis, infundibular interface mural folliculitis and periglandular lymphocytic infiltrate. Complete blood count, serum chemistry profile, urinalysis, urine protein/creatinine ratio and serum antinuclear antibody test were unremarkable. The absence of systemic signs and unremarkable laboratory tests excluded concurrent systemic lupus erythematosus. Treatment of ECLE was initiated with oral MMF (22 mg/kg, twice daily); MMF dosage was decreased (10 mg/kg; twice daily) after 7 days when the patient developed diarrhoea. Within three weeks of starting MMF therapy, a marked improvement in lameness and a moderate decrease in erythema and scaling was observed. After three months, erythema, scaling and follicular casts completely resolved and the patient's ECLE remains in complete remission with twice daily MMF. To the best of the authors' knowledge, this is the first reported case of successful treatment of ECLE with mycophenolate mofetil as a single-agent therapy.
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Comparing the cost of management of canine atopic dermatitis: canine atopic dermatitis immunotherapeutic versus other therapies K. K. MWACALIMBA, A. HILLIER and D. AMODIE Zoetis LLC, Parsippany, NJ, USA Canine atopic dermatitis (AD) is a commonly diagnosed condition in veterinary dermatology, requiring comprehensive management and frequent rechecks. Furthermore, the cost of medical management may be a concern for both pet owners and veterinarians. An observational retrospective pharmacoeconomics study was conducted to compare the cost of AD management in dogs for the 12 months prior to canine atopic dermatitis immunotherapeutic (CADI) ( Skin barrier function is believed to play an important role in atopic dermatitis (AD). Debate still exists whether there may be some primary barrier dysfunction in canine AD or whether the impairment is purely secondary to inflammation. Transepithelial electrical resistance (TEER) is used extensively in human medicine as a measurement of skin barrier integrity and tight protein junction function without the influence of inflammation derived by leucocytes recruited in the skin. To the best of the authors' knowledge, this parameter has not been assessed in canine AD. Thus, the purpose of this study was to investigate TEER keratinocyte cell cultures from biopsies of normal and atopic dogs. Primary cell cultures from five normal and five atopic dogs grown on transwell inserts were measured up to 13 days after confluence using a TEER device that quantitatively measures the integrity of tight junctions and cell barriers in epithelial cell monolayers. Measurements were taken daily and ranged from 3 to 2,359 ohms/cm. Normal cells were significantly higher than atopic cells with an average peak at Day 6 of 1954 ohms/cm; highest levels of resistance for atopic cells were 520 ohms/cm on Day 13. Using two-way repeated measures ANOVA there was a significant difference over time (P < 0.0001) and between groups (P < 0.0001). In conclusion, there is a significant difference in barrier function between normal and atopic keratinocytes. Future studies will need to address the cause of this intrinsic difference in behaviour of atopic keratinocytes starting with expression of tight protein junction overtime in cell culture.
Investigation on the effects of current treatments for canine atopic dermatitis on skin barrier function in a colony of atopic beagles We aimed to investigate the effect of currently approved treatments for canine atopic dermatitis on skin barrier function. Atopic beagles (n = 19) were randomly divided into five groups and challenged with allergen (Dermatophagoides farinae, 12.5 mg/dog/challenge) twice weekly for four weeks. Treatment groups included oclacitinib (n = 4, per os (p.o.), 0.5 mg/kg twice daily for two weeks, once daily for two weeks), ciclosporin (n = 4, p.o., 5 mg/kg once daily for 28 days), lokivetmab (n = 4, one subcutaneous (s.c.) injection, 2 mg/kg, on first day of challenge); prednisone (n = 4, p.o., 0.5 mg/kg twice daily for two weeks, 0.5 mg/kg once daily for one week, 0.5 mg/kg every other day for one week) and control group (n = 3, no treatment). Skin barrier function was assessed on days 0, 14 and 28 on three sites (pinnae, axillae, inguinal area). Evaluations included dermatitis [Canine Atopic Dermatitis Extent and Severity Index (CADESI)-03], pruritus, transepidermal water loss (TEWL, closed chamber device) and hydration (corneometer). Significant decrease of hydration from baseline was found in control and prednisone groups in axillae on Day 14 (P = 0.004 and P = 0.027, respectively). Lokivetmab significantly decreased hydration on Day 28 compared to baseline (P = 0.027) and with controls (P = 0.023) in pinnae. Ciclosporin significantly increased TEWL from baseline to Day 14 (P = 0.029) and to Day 28 (P = 0.031) in axillae. Oclacitinib and lokivetmab did not significantly change TEWL overtime. Controls significantly increased TEWL in axillae on Day 28 (P = 0.0237). CADESI-03 correlated with TEWL (r = 0.22; P = 0.0043) and pruritus scores (r = 0.22; P = 0.0283). Hydration did not correlate with any parameters. In conclusion, none of the treatments improved skin barrier function parameters using technologies currently available.
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Characterization of skin microbiota from superficial pyoderma forms in dogs Canine superficial bacterial pyoderma is a common and recurrent disease characterized by three clinically and histopathologically distinct forms: superficial bacterial folliculitis (SBF), bullous impetigo (BI) and exfoliative pyoderma-associated epidermal collarettes (EC). Based on traditional culture sampling, Staphylococcus pseudintermedius is considered the major pathogen in canine superficial pyoderma. This study aimed to evaluate the skin microbiome and staphylococcal diversity of SBF-(12 lesions, eight dogs) and EC-associated (nine lesions, six dogs) superficial pyoderma phenotypes in dogs. Nextgeneration sequencing was performed on DNA extracted from superficial pyoderma lesions with primers targeting the V1-3 region of the bacterial 16s rRNA gene; sequences were processed in MOTHUR using the RDP classifier and Silva reference alignment. Staphylococcus spp. accounted for 43% and 26% of the total sequences from SBF and EC samples, respectively. Staphylococcal sequences were further classified using a Staphylococcus spp. reference database as S. pseudintermedius (87%), S. pasteuri (3%), S. felis (3%) and S. epidermidis (2%). Relative abundance of Staphylococcus spp. was found to be significantly (P < 0.01) higher in the EC samples relative to the SBF samples, whereas Corynebacterium spp. abundance was increased in SBF samples (P < 0.05). As expected, SBF and EC lesions contained higher densities of Staphylococcus spp. measured by quantitative PCR than healthy canine skin (eight samples, four dogs) (P < 0.01 and P < 0.01, respectively). These results characterize differential contributions of microbial dysbiosis during SBF and EC pyoderma lesion formation; whether Corynebacterium spp. contributes to the SBF pathophysiology or merely reflects the abnormal environment needs to be further investigated.
Investigation on the effects of oclacitinib and lokivetmab, a caninized anti-IL-31 monoclonal antibody, on IL-31 serum levels in a colony of atopic beagles R. MARSELLA, K. AHRENS, R. SANFORD, A. TRUJILLO and M. DORR Blanche Saunders Dermatology Laboratory, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA Interleukin-31 (IL-31) has attracted attention as mediator of pruritus in canine atopic dermatitis (AD) and is targeted in current therapies. We aimed to investigate: (1) IL-31 serum levels during allergen challenge and oclacitinib (Apoquel â ) or lokivetmab (Cytopoint â ); (2) correlation between serum IL-31 and pruritus scores in a colony of atopic dogs. Eleven atopic beagles were challenged with allergen (Dermatophagoides farinae) twice weekly for 28 days while randomly assigned to receive either oclacitinib (n = 4, per os, 0.5 mg/kg twice daily for two weeks, then once daily for two weeks), or lokivetmab (n = 4, subcutaneous, one injection, on day of first challenge, 2 mg/ kg) or no treatment (n = 3). Blood was drawn on days 0, 14 and 28 to measure serum IL-31 using a validated ELISA for canine IL-31. Pruritus was scored weekly [pruritic acts recorded by cameras over a 30-min period and global score (pruritus Visual Analog Scale (PVAS)]. No significant change was detected overtime for serum IL-31 during the course of either therapy or in controls even if controls developed average 4.5 PVAS with some recordings of 10 PVAS. No correlation was found between pruritus and serum IL-31 on any day. In this pilot study, serum IL-31 does not appear to correlate with disease severity nor predict clinical response as the dogs in our study clinically responded to lokivetmab injection (0 PVAS on weeks 3 and 4) and to oclacitinib. It is speculated that tissue concentrations may be more relevant in dogs than serum levels. Larger studies are necessary to continue to evaluate these parameters in canine AD. Limited information is available on intradermal testing (IDT) threshold concentrations (TCs) for common allergens from different allergen extract suppliers. The objective of this study was to determine and compare the TCs for IDT allergen extracts in healthy dogs from two allergen suppliers. We hypothesized that IDT TCs would vary by allergen extract and manufacturer. Allergen suppliers were ALK-Abell o and Stallergenes Greer. IDT was performed in 35 healthy nonallergic dogs. Eleven allergens from each company were diluted to six protein nitrogen unit concentrations. Reactions were scored subjectively (0-4+) and objectively as the average of the vertical and horizontal diameter of each reaction. Subjective and objective measurement concordance was determined for each company. Threshold concentrations were defined as the highest concentration of an allergen where ≤10% of dogs had a positive subjective reaction (≥2+) at 15 min. Using generalized estimating equations, the TCs of Chenopodium album, Ulmus americana, Juglans nigra, Acer negundo, Juniperus virginiana, Quercus alba, Sorghum halepense, Phleum pratense and Dermatophagoides farinae were determined for ALK-Abell o extracts. The TCs for Ambrosia spp., Chenopodium album, Plantago lanceolata, Ulmus americana, Juglans nigra, Acer negundo, Sorghum halepense and Phleum pratense were identified for Greer extracts. Not all TCs could be determined for either company's extracts. Percentage concordance of the objective measurement with the subjective score was 77.3% for ALK and 75% for Greer allergens. The TCs differed between allergens and manufacturers; therefore, not all allergens from different manufacturers are interchangeable nor should all allergens in an IDT panel be used at the same concentration. Cytokines produced from T-helper type II (Th2) lymphocytes are thought to contribute to the clinical signs of canine allergic skin disease (e.g. Interleukin (IL)-4, IL-5, IL-13 and IL-31). These cytokines activate Janus kinases (JAK) and signal transducer and activator of transcription (STAT) pathways in cells. Oclacitinib is a selective Janus kinase (JAK)-1 inhibitor that potently inhibits the ability of canine IL-31 to activate STAT3. Previous reports demonstrated that oclacitinib also could inhibit IL-4 and IL-13 function; however, human cytokines and cell systems were used in these experiments. The objective of this study was to determine the ability of oclacitinib to inhibit the function of canine IL-4 and IL-13 in the canine DH82 cell line. When the DH82 cells were treated with these cytokines, phosphorylation (activation) of STAT3, 5 and 6 were detected in cells using AlphaScreen technology (PerkinElmer). When DH82 cells were treated with varying concentrations of oclacitinib (0.0001-10 lM), phosphorylation of each STAT was inhibited in a dosedependent manner. The concentration at which 50% of the phosphosphorylated STAT signal (induced by IL-4 or IL-13) was inhibited (IC 50 ) by oclacitinib varied depending on the STAT protein analysed. Oclacitinib most potently inhibited IL-4 and IL-13-induced STAT3 and STAT5 (IC 50 = 51-57 nM) and was least potent at inhibiting IL-4 and IL-13-induced STAT6 (IC 50 = 680 and 540 nM, respectively). These data demonstrate that oclacitinib can inhibit multiple STAT pathways in cells treated with IL-4 or IL-13, suggesting that this activity may contribute to its efficacy in dogs with allergic skin disease. Interleukin-31 (IL-31) is accepted as an important cytokine associated with the sensation of pruritus associated with atopic dermatitis in both dogs and humans. IL-31 signals via a receptor incorporating the cytokinespecific subunit IL-31 receptor alpha (IL-31RA). In dogs, four IL-31RA mRNA splice variants encode two protein isoforms: the full-length isoform X1 and the truncated isoform X2 which lacks the N-terminal signal peptide and parts of the cytokine binding domain. The aim of this study was to examine transcription of these two IL-31RA isoforms in the skin of atopic laboratory dogs following acute allergen challenge. Ten atopic laboratory beagles kept in low-allergen conditions were challenged epicutaneously with Dermatophagoides farinae to provoke moderate allergic inflammation. Skin biopsy samples were collected prior to challenge and at 3 h, 3 and 10 days afterwards. Real-time PCR was used to examine IL-31RA isoform transcription. Assay specificity was confirmed by PCR product sequencing and melt curve analysis. Transcription of both IL-31RA isoforms was significantly reduced at 3 h and 3 days following allergen challenge (P < 0.001), but was not significantly different from baseline on Day 10. Transcription of IL-31RA X2 was greater than that of IL-31RA X1 throughout the study (P < 0.005). In this study, transcription of both IL-31RA isoforms was inversely correlated with clinical signs of allergic inflammation (P < 0.005). Modulation of IL-31RA expression has also been demonstrated in human atopic keratinocytes. Further studies are needed in dogs to understand the role of cytokines on receptor modulation. FDA approved canine otitis externa treatments are limited in variety and may contain ototoxic ingredients. Bacterial resistance is of continued concern, thus it would be ideal if non-ototoxic agents could be combined antibiotics for a synergistic effect, requiring lower concentrations of antibiotics to treat infections. Evidence of synergism and antagonism between N-acetylcysteine and various classes of antibiotics has been reported; our group was interested in further examining these interactions. The study aim was to determine if N-acetylcysteine, an otoprotective and antimicrobial compound, has synergistic activity when combined with enrofloxacin or gentamicin in vitro against bacterial isolates causing canine otitis externa. Twenty two bacterial isolates from canine clinical cases were identified and tested: seven Staphylococcus pseudintermedius, 12 Pseudomonas aeruginosa and three Corynebacterium spp. Each isolate was grown on blood agar for 24 h and transferred to Mueller-Hinton broth, resulting in a final concentration of 10 5 cfu/mL. Each well was inoculated with 50 lL of bacterial suspension. N-acetylcysteine was diluted in Mueller-Hinton broth to a starting concentration of 160 mg/mL, and both enrofloxacin and gentamicin were diluted to 64 lg/mL. Serial microdilution assays were performed in triplicate with negative controls for all isolates tested. For N-acetylcysteine, the minimum inhibitory concentration (MIC) values for all isolates tested ranged from 5 to 20 mg/ mL, enrofloxacin MIC values ranged from 0.03 to ≥8 lg/mL and gentamicin MIC values ranged from ≤0.06 to ≥32 lg/mL. When combined, N-acetylcysteine with enrofloxacin and N-acetylcysteine with gentamicin resulted in both synergism and antagonism at the concentrations tested. Source of funding: Self-funded.
Twenty-seven OTUs were over-represented in healthy ears, including Romboutsia, Megamonas and Faecalibacterium. The otic microbiota is much more complex than has been identified with previous culture-based studies, and otitis externa is accompanied by broad and complex differences in the microbiota.
The filaggrin story continued: investigation on filaggrin and filaggrin 2 in normal and atopic dogs Currently two proteins with filaggrin-like characteristics are described. We describe their distribution and morphology comparatively in normal and atopic canine keratinocytes cultures using fluorescently labelled antibodies to make tridimensional videos. At initial confluence, filaggrin-1 was nuclear and regularly organized in normal keratinocytes, whereas it was both cytoplasmic, nuclear and irregularly structured in atopic keratinocytes. Four days later in normal keratinocytes distribution was primarily nuclear with some detection in the cytoplasm, whereas in atopics it was all cytoplasmic. Filaggrin-2, in both normal and atopic keratinocytes, was more cytoplasmic and less abundant than filaggrin-1 and stained less in atopics. On Day 4, in normal keratinocytes filaggrin-2 was detectable as discrete and well-defined filaments, whereas it looked decreased, patchy and irregularly distributed in cytoplasm of atopic keratinocytes. Using qRT-PCR, higher gene expression for both filaggrins was found in atopics compared to normal. Next, biopsies from atopic beagles before (Day 0) and after exposure to allergen (Days 3 and 10) were stained by immunohistochemistry. Photographs were scored blindly for intensity, patchiness and distribution. No significant difference in intensity existed between filaggrin-1 and 2, overtime. Filaggrin-1 patchiness significantly increased at peak of clinical reactions (Day 3). Both filaggrins were variably detected in both stratum granulosum and spinosum. Filaggrin-2 also was detected in stratum basale in 10% of slides. PCR showed increased gene expression for filaggrin-1 after allergen challenge (Day 10). It is preliminarily concluded that altered organization of filaggrin filaments exists in atopic keratinocytes and that this may lead to increased production.
Source of funding: Self-funded. In order to assess whether interleukin-31 (IL-31) may play a role in feline allergic dermatoses, serum samples from cats with a presumptive diagnosis of allergic dermatitis (n = 73) were collected and the circulating IL-31 concentration was compared to age-matched controls (n = 17). Collection occurred at 10 independent clinics spread across the United States. Inclusion criteria for a presumptive allergic dermatitis diagnosis included cats with both flea and nonflea hypersensitivity disorders or allergic disorders of unknown origin. Additional inclusion criteria included the cessation of current treatments such as glucocorticoids or ciclosporin for at least two weeks prior to sample collection. The mean circulating IL-31 level was 8,798 fg/mL for cats with allergic dermatitis compared to 205 fg/mL in age-matched controls. These data demonstrate increased IL-31 levels in allergic cats and are suggestive that IL-31 plays a role in feline allergic disease; however, a causative role of IL-31 in feline allergic disease remains to be determined. A similar analysis performed in dogs with atopic dermatitis demonstrated that mean circulating levels in atopic dogs was 13,152 fg/mL compared to 465 fg/mL in laboratory beagles. A 10-year-old, spayed female shih tzu presented with an 85-day history of progressive erythema and multiple crusts. The dog had signs of hyperadrenocortism which was diagnosed 55 days prior to presentation. She then received 55 days of trilostane [Vetoryl â ; 10 mg/kg, per os (p.o.), once daily]; however, this was discontinued due to poor response. In addition to generalized alopecia from hyperadrenocorticism, erythematous plaques and crusts were noted on the trunk, head and food pads. Lesional impression smears revealed numerous acantholytic keratinocytes and non-degenerate neutrophils. Laboratory examination showed neutrophilic leucocytosis and increased alkaline phosphatase activity. Histopathological findings demonstrated subcorneal pustules with acantholytic keratinocytes, as well as epidermal hyperkeratosis and hair follicles containing keratin and cellular debris. Based on these findings, this dog with hyperadrenocorticism was diagnosed with concurrent pemphigus foliaceus (PF). Because of the desire to avoid corticosteroids, the dog was treated with azathioprine (2 mg/kg, p.o., once daily), ciclosporin-modified (7 mg/kg, p.o., once daily) and ketoconazole (5 mg/kg, p.o., once daily). The ketoconazole was chosen to help manage the hyperadrenocorticism and elevate ciclosporin levels. By Day 80 post post-treatment, more than 70% of the dermatological signs were improved without adverse events. Although this partial response had been maintained for an additional 35 days, the dog was then lost to follow-up. To the best of our knowledge, this is the first case that describes a dog with concurrent PF and hyperadrenocorticism that partially responded to combination therapy with azathioprine, ciclosporin-modified and ketoconazole. These medications may be considered in other dogs diagnosed with concurrent PF and hyperadrenocorticism. Limited information exists comparing antimicrobial activity of shampoos. The study objective was to determine the residual antimicrobial activity on canine hairs treated with a single application of shampoo. Forty eight privately owned dogs were bathed with a control shampoo 3 days prior to group assignment. Dogs were then randomly assigned to one of four treatment groups: 2% chlorhexidine gluconate/2% miconazole nitrate (Malaseb â ); 3% chlorhexidine gluconate/0.5% climbazole (DOUXO â Chlorhexidine); 2% chlorhexidine gluconate/2% miconazole nitrate/tromethamine USP disodium EDTA (MICONAHEX+TRIZ â ); or 2% chlorhexidine gluconate/ 2% miconazole nitrate/microsilver (BioHex TM ). They were bathed by a blinded investigator using 10 mL of shampoo per 10 kg body weight. Hair was collected prior to medicated bathing, then 1 h, 2, 4 and 7 days post-bathing, weighed and placed onto Mueller-Hinton with 2% NaCl agar streaked with Staphylococcus pseudintermedius or Sabouraud's dextrose agar streaked with Malassezia pachydermatis. Duplicate plates were incubated for 24 and 72 h, respectively, and the zone of inhibition measured. Hair collected prior to bathing did not demonstrate microbial inhibition, whereas after treatment samples exhibited residual antifungal and antibacterial activity throughout the study for all groups. No statistical differences were observed in zones of inhibition between shampoos against M. pachydermatis. There were significant treatment differences for S. pseudintermedius. The largest zones of inhibition were from hairs bathed with Malaseb â and BioHex
TM
. These results indicate formulation differences appear to affect the residual antibacterial but not the antifungal efficacy of these four shampoos. Further studies are needed to determine if these in vitro differences correlate to differences in clinical efficacy. The study purpose was to investigate the therapeutic efficacy of white rose petal extracts (WRPE) in canine atopic dermatitis (cAD). Seventeen atopic dogs and four healthy beagles were enrolled. Experimental dermatitis was induced three times (days 1, 4 and 7) in the beagles by intradermal injections of histamine dihydrochloride, compound 48/80 and substance P acetate hydrate. The atopic dogs had WRPE cream (1%, n = 9) or solution (0.5%, n = 4 or 1%, n = 4), applied once daily; all the beagles had WRPE solution (1%) or WRPE cream (1%) or control (0% WRPE) applied thrice daily. In atopic dogs, clinical assessments were performed by measuring transepidermal water loss (TEWL) and using modified Canine Atopic Dermatitis Extent and Severity Index (CADESI)-04 and pruritus Visual Analog Scale (PVAS) on days 0, 14 and 28. In the beagles, TEWL and wheal diameter were measured on days 1, 4 and 7. Histopathological examination was performed before (Day 0) and after topical treatments (days 2 and 8). In atopic dogs, 1% solution decreased TEWL on Day 28 compared to Day 0 (P < 0.05), whereas PVAS and modified CADESI-04 scores were not changed. In the beagles, TEWL significantly increased with compound 48/80-induced dermatitis (P < 0.001), but the increases were significantly less in the 1% cream-treated lesions compared to control-treated lesions (P = 0.04). The wheal diameter of histamine-induced lesions significantly decreased following application of 1% cream (P < 0.001). Histopathologically, the 1% cream decreased oedema and inflammation in histamine-induced lesions. Therefore, WRPE may be effective in restoring skin barrier function in CAD and reducing histamine-induced inflammation.
